News

bit.bio secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.

bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

bit.bio is partnering with the iGEM student competition, aimed at advancing the field of synthetic biology.

Our CEO Mark Kotter talks to Drug Discovery World about different approaches to synthetic biology and its applications in drug dis...

The Decoding Bio Snapshot profiles 40 companies operating at the intersection of computation and biology.

The discussion covers regenerative medicine, cell therapies and how human cells can transform research and drug development.